Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes
Carol J. Levy, Dan Raghinaru, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Luis Casaubon, Donna Desjardins, Camilla Levister, Grenye O’Malley, Corey Reid, John W. Lum, Craig Kollman, Roy W. Beck
Abstract
The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70-180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.
Topics & Concepts
MedicineGlycemicHypoglycemiaInsulinBolus (digestion)Insulin deliveryType 1 diabetesInsulin pumpBasal (medicine)Basal insulinDiabetes mellitusInternal medicineType 2 diabetesEndocrinologyAnesthesiaDiabetes Management and ResearchPancreatic function and diabetesReceptor Mechanisms and Signaling